VIC Foundry, Inc. Receives NIH RADx Funding for Development of an At-home Molecular Diagnostic Test for COVID-19
Share Article
VIC Foundry, in collaboration with Sandia National Laboratories, is developing a self-contained isothermal nucleic acid amplification test to address an unmet need for at-home testing of COVID-19 infection.
VIC Foundry’s innovative designs for a low-cost at-home COVID-19 test
Funding for the project is being provided by the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Tech program to support new approaches to nationwide COVID-19 testing and surveillance ALBUQUERQUE, N.M. (PRWEB) February 16, 2021 This diagnostic technology uses Sandia’s patented QUASR (Quenching of Unincorporated Amplification Signal Reporters) assay with sequence-specific fluorescence detection, combined with VIC Foundry’s innovative designs for a low-cost test cartridge and monit
Diabeloop SA. and SFC Fluidics Inc. announce development agreement for the United States
Share Article
SFC Fluidics Inc., developer of an Alternate Controller Enabled (ACE) insulin delivery pod and Diabeloop, pioneer in therapeutic artificial intelligence, are partnering to integrate the SFC ACE insulin pod into Diabeloop’s Automated Insulin Delivery solution. The agreement plans for a full US-adaptation of the system with a common mission - to bring the next generation of diabetes management to patients with type 1 diabetes in the United States.
“We are encouraged that our relationship with Diabeloop continues to progress towards a meaningful goal of a marketed artificial pancreas in the US”, commented Don Jackson, CFO of SFC.
CardioWise™ Receives US FDA 510(k) Clearance for Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ) Heart Function Analysis Software
Share Article
CardioWise, Inc., is pleased to announce Clearance of its 510(k) application by the US Food and Drug Administration (FDA) for its heart function analysis software, Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ). CardioWise can now market the SQuEEZ analysis to provide give caregivers an easy-to-read, quantitative 4D color model that allows physicians to make better, more informed decisions about their patients’ care.” -Jack Coats, CEO of CardioWise, Inc. FAYETTEVILLE, Ark. (PRWEB) January 06, 2021 The 510(k) premarket notification letter indicates that the FDA has determined that SQuEEZ may be legally marketed in interstate commerce according to its indications for use. SQuEEZ is an image analysis software application for cardiac Computer T